VANCOUVER, CANADA – March 3, 2016 – Evasc Neurovascular Enterprises ULC today announced today the commencement of the European eCLIPs Safety, Feasibility, and Efficacy Study (EESIS), including the first case under the EESIS study.
The EESIS study is a designed to evaluate the safety, technical feasibility, and efficacy of the eCLIPs Bifurcation Remodeling System for the treatment of bifurcation intracranial aneurysms. The study will be carried out in Denmark, Germany, Netherlands, and the United Kingdom, and is anticipated to run through mid-2018.
“We are excited to be running our first formal clinical trial, which will provide us with important human data on the safety, usage, and efficacy of eCLIPs,” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc.
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in over 25 patients in Canada and Europe.
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received CE mark approval in 2016. Evasc is headquartered in Vancouver, Canada.
Evasc Neurovascular is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, email@example.com.